<DOC>
	<DOCNO>NCT01847976</DOCNO>
	<brief_summary>The purpose study see woman bone metastasis breast cancer benefit addition doxycycline standard bone-targeted therapy . Participants ask take 100 mg Doxycycline orally twice day 12 week . Blood tissue collection define mechanism benefit .</brief_summary>
	<brief_title>Combining Doxycycline With Bone-Targeted Therapy Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>Potential candidate trial must receive intravenous bisphosphonate therapy ( i.e . pamidronate zoledronic acid ) subcutaneous denosumab least 3 month . Baseline patient characteristic record screen serum PTH ( rule primary hyperparathyroidism ) vitamin D ( 25OH-vit D ) record . In order fulfill study objective , serum take CTX ( fast morning blood sample ) , P1NP BSAP well optional translational study ( e.g . MMP TIMP level ) . Optional urine take NTX . Questionnaires also complete symptom ( Brief pain inventory ( BPI ) [ 26 ] FACT-BP [ 27 ] ) analgesic use ( converted oral Morphine-equivalent dose ) . The serum , urine questionnaire data collect : baseline , week 4 , 8 , 12 . In addition , toxicity information question occurrence skeletal related event perform baseline , week 4 , 8 12 . At baseline week 12 patient also bone marrow aspirate trephine biopsy perform posterior iliac crest . These specimen use ER , PR Her2 analysis ( FISH ) marker apoptosis ( TUNEL ) proliferation ( Ki67 ) also optional translational study provide tumour cell present .</detailed_description>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>1 . Patients metastatic breast cancer radiologically confirm bone metastasis . 2 . On intravenous bonetargeted therapy ( bisphosphonate subcutaneous ( SC ) denosumab ) least 3 month . 3 . ECOG â‰¤ 2 4 . Life expectancy &gt; 3 month . 5 . No change type systemic chemotherapy , endocrine therapy biological therapy ( i.e . trastuzumab , lapatinib ) treatment 4 week prior study entry anticipate change 4 week enter study . ( Markers bone formation affect change systemic therapy ) . 6 . Ability provide inform consent complete study evaluation . 1 . Prior hypersensitivity either IV bisphosphonate therapy SC denosumab , doxycycline tetracycline . 2 . Patients myasthenia gravis 3 . Patients take hepatic enzyme inducer phenytoin , barbiturates carbamazepine 4 . Patients rapidly progressive nonbone metastasis delay change systemic anticancer treatment first 4 week study could detrimental impact patient outcome . 5 . Women child bear potential unwilling use acceptable method contraception study . 6 . Pregnancy lactation . 7 . Clotting disorder would preclude bone marrow aspirate trephine biopsy . ( Patients Fragmin Daltaperin allow study )</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>breast</keyword>
	<keyword>bone pain</keyword>
</DOC>